I've seen it in a few slide presentations now....in the R&R presentation its #27, the one where they list the pipeline valuations:

Torcetrapib$13B

Dalcetrapib $8B

Daralpadib$10B

Evacetrapib $8B

I'm calling it the whiny slide.....as if Resverlogix is whining....''What about us''??? ''How come our valuation isn't in the billions''??? ''Its not fair''!!!

Of course, as noted on the slide.....those 4 all FAILED. What's the old line about ''fool me once''? The market hasn't assigned lofty valuations for drugs targetting Cardio Vascular diseases once, not even twice....4x it assigned valuations ranging from $8 Billion to $13 Billion.

Could it simply be, that after seeing highly touted drugs fail four times already....its not once bitten or twice, but four times bitten, 5th time shy.

If the goal is to talk Apebetalone up as a potential treatment to lower MAC events....then why point out all the previous failures?